

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal (STA)

## Enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with chemotherapy

## Matrix of consultees and commentators

| Consultees   | Commentators (no right to submit or appeal)   |
|--|---|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Astellas Pharma (Enzalutamide)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Bob Champion Cancer Trust</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Equalities National Council</li> <li>• Everyman</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Orchid</li> <li>• PCaSO – Prostate Cancer Network</li> <li>• Prostate Cancer UK</li> <li>• Prostate Help Association</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tackle Prostate Cancer</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association of Urological Nurses</li> <li>• British Association of Urological Surgeons</li> </ul> | <p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (prednisolone)</li> <li>• Alliance Pharma (prednisolone)</li> <li>• Amdipharm UK (prednisolone)</li> <li>• Intrapharm Laboratories (prednisolone)</li> <li>• Janssen (abiraterone)</li> <li>• Wockhardt UK (prednisolone)</li> <li>• Zentiva UK (prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Prostatic Diseases and Urologic Cancers Group</li> <li>• Health Research Authority</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> </ul> |

| Consultees  | Commentators (no right to submit or appeal)  |
|---|--|
| <ul style="list-style-type: none"> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Prostate Group</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society of Urogenital Radiology</li> <li>• British Uro-Oncology Group</li> <li>• Cancer Research UK</li> <li>• Pelican Cancer Foundation</li> <li>• Prostate Cancer Advisory Group</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> <li>• Urology Foundation</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Gateshead CCG</li> <li>• NHS Liverpool CCG</li> <li>• Welsh Government</li> </ul> | <ul style="list-style-type: none"> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Ovarian &amp; Prostate Cancer Research Trust</li> <li>• Pro Cancer Research Fund</li> <li>• Prostate Cancer Research Centre</li> <li>• Research Institute of the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Aberdeen Health Technology Assessment Group</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul> |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

#### **Definitions:**

##### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

##### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.